AbbVie Inc.
AbbVie Announces Expected Earnings Miss Due to Acquired IPR&D and Milestones Expense
Summary
AbbVie Inc. disclosed preliminary estimates for the first quarter of 2024, indicating an expected GAAP and non-GAAP earnings miss of $0.08 per share due to acquired IPR&D and milestones expense of $164 million. The company updated its full-year 2024 adjusted diluted earnings per share guidance to a range of $10.97 to $11.17, including the impact of the first quarter expense. Final results are pending and subject to the company's financial statement closing procedures.
Profitelligence Alerts
Get alerts for ABBV
Be first to know when AbbVie Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About AbbVie Inc.
AbbVie Inc. is a prominent biopharmaceutical company that focuses on developing innovative therapies addressing some of the world's most challenging diseases. Originating from a 2013 spinoff of Abbott Laboratories, AbbVie is dedicated to the research and production of pharmaceutical products designed to improve patient outcomes globally. With a robust portfolio, the company specializes in treatments for autoimmune conditions, infectious diseases, oncology, and ophthalmology. Among its flagship products is Humira, widely used for rheumatoid arthritis and inflammatory conditions, which has established AbbVie as a leader in this therapeutic area. The company also invests heavily in research and development, resulting in a pipeline of promising drugs designed to cater to unmet medical needs. AbbVie operates in North America and international markets, serving healthcare providers, researchers, and patients. Its commitment to scientific innovation and high-quality manufacturing standards has positioned it as an influential entity in the healthcare and pharmaceuticals sector.
Official SEC Documents
Advertisement